JP2012521198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521198A5 JP2012521198A5 JP2012501034A JP2012501034A JP2012521198A5 JP 2012521198 A5 JP2012521198 A5 JP 2012521198A5 JP 2012501034 A JP2012501034 A JP 2012501034A JP 2012501034 A JP2012501034 A JP 2012501034A JP 2012521198 A5 JP2012521198 A5 JP 2012521198A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- agent
- composition
- cry2
- cry1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 18
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 11
- 101150078024 CRY2 gene Proteins 0.000 claims description 11
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 11
- 101150102464 Cry1 gene Proteins 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- 102100029376 Cryptochrome-1 Human genes 0.000 claims description 8
- 102100026280 Cryptochrome-2 Human genes 0.000 claims description 8
- 101000919351 Homo sapiens Cryptochrome-1 Proteins 0.000 claims description 8
- 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 8
- 230000002060 circadian Effects 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 20
- 230000027288 circadian rhythm Effects 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 4
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 4
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- KCYOZNARADAZIZ-CWBQGUJCSA-N 2-[(2e,4e,6e,8e,10e,12e,14e)-15-(4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-2-yl)-6,11-dimethylhexadeca-2,4,6,8,10,12,14-heptaen-2-yl]-4,4,7a-trimethyl-2,5,6,7-tetrahydro-1-benzofuran-6-ol Chemical compound O1C2(C)CC(O)CC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C1C=C2C(C)(C)CCCC2(C)O1 KCYOZNARADAZIZ-CWBQGUJCSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- KCYOZNARADAZIZ-PPBBKLJYSA-N Cryptochrome Natural products O[C@@H]1CC(C)(C)C=2[C@@](C)(O[C@H](/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(\C)/[C@H]3O[C@@]4(C)C(C(C)(C)CCC4)=C3)/C)\C)/C)C=2)C1 KCYOZNARADAZIZ-PPBBKLJYSA-N 0.000 description 2
- 108010037139 Cryptochromes Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 2
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 2
- KCYOZNARADAZIZ-XZOHMNSDSA-N beta-cryptochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C3OC4(C)CCCC(C)(C)C4=C3 KCYOZNARADAZIZ-XZOHMNSDSA-N 0.000 description 2
- 150000004283 biguanides Chemical group 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16221909P | 2009-03-20 | 2009-03-20 | |
| US61/162,219 | 2009-03-20 | ||
| PCT/US2010/028196 WO2010108195A1 (en) | 2009-03-20 | 2010-03-22 | Methods for modulating metabolic and circadian rhythms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521198A JP2012521198A (ja) | 2012-09-13 |
| JP2012521198A5 true JP2012521198A5 (enExample) | 2013-03-28 |
Family
ID=42740037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501034A Pending JP2012521198A (ja) | 2009-03-20 | 2010-03-22 | 代謝リズムおよび概日リズムを調整する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120134985A1 (enExample) |
| EP (1) | EP2408906A4 (enExample) |
| JP (1) | JP2012521198A (enExample) |
| AU (1) | AU2010226386A1 (enExample) |
| CA (1) | CA2753897A1 (enExample) |
| WO (1) | WO2010108195A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5440434B2 (ja) * | 2010-07-22 | 2014-03-12 | オムロンヘルスケア株式会社 | 体重管理装置 |
| KR101994145B1 (ko) * | 2013-01-28 | 2019-07-01 | 한올바이오파마주식회사 | Ν１-고리아민-ν５-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 시차증후군의 예방 또는 치료용 약학 조성물 |
| KR102088001B1 (ko) * | 2013-05-23 | 2020-03-12 | 이뮤노메트테라퓨틱스 인코포레이티드 | N1-고리아민-n5-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 섬유화 예방 또는 치료용 약학 조성물 |
| KR101542324B1 (ko) * | 2014-04-09 | 2015-08-05 | 동아대학교 산학협력단 | 손상된 dna의 회복 속도 비교를 위한 정보 제공 방법 |
| KR101947890B1 (ko) * | 2016-01-28 | 2019-02-13 | 고려대학교 산학협력단 | 생체 시계 산출 방법 및 시스템 |
| KR102441334B1 (ko) | 2017-08-01 | 2022-09-06 | 삼성전자주식회사 | 생체 정보 처리 장치 및 방법 |
| EP4065100B1 (en) * | 2019-12-30 | 2024-05-08 | KOC Universitesi | Destabilizer of cry1 for the treatment of circadian rhythm associated diseases and disorders |
| WO2022255955A1 (en) | 2021-05-31 | 2022-12-08 | Koc Universitesi | ((1s,9s)-11-{[4-(1,3-benzodioxol-5-ylamino)-8-methyl-2-quinazolinyl]methyl} -7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one) as a stabilizer of crys for the treatment of circadian rhythm associated diseases and disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7021A (en) * | 1850-01-15 | Substitute for the clevis | ||
| DE3466215D1 (en) * | 1983-05-18 | 1987-10-22 | Univ Monash | The use of melatonin for the manufacture of a medicament |
| WO2001007654A1 (en) * | 1999-07-22 | 2001-02-01 | The General Hospital Corporation | Method for identifying compounds which modulate circadian rhythm |
| US20030212014A1 (en) * | 2000-08-09 | 2003-11-13 | Neil Ruderman | Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds |
| EP1442064A2 (en) * | 2001-10-19 | 2004-08-04 | Incyte Genomics, Inc. | Kinases and phosphatases |
| US7427489B1 (en) * | 2002-06-17 | 2008-09-23 | The Scripps Research Institute | Screening assay to identify modulators of the sleep/wake cycle |
| US20050244517A1 (en) * | 2003-11-05 | 2005-11-03 | Santarus, Inc. | Combination of proton pump inhibitor and sleep aid |
| WO2007082309A2 (en) * | 2006-01-16 | 2007-07-19 | The Board Of Regents Of The University Of Texas System | Adenosine monophosphate for inducing torpor in a subject |
| AU2010226417A1 (en) * | 2009-03-20 | 2011-10-13 | The Salk Institute For Biological Studies | Methods for modulating circadian rhythms |
-
2010
- 2010-03-22 AU AU2010226386A patent/AU2010226386A1/en not_active Abandoned
- 2010-03-22 JP JP2012501034A patent/JP2012521198A/ja active Pending
- 2010-03-22 WO PCT/US2010/028196 patent/WO2010108195A1/en not_active Ceased
- 2010-03-22 CA CA2753897A patent/CA2753897A1/en not_active Abandoned
- 2010-03-22 EP EP10754243A patent/EP2408906A4/en not_active Withdrawn
- 2010-03-22 US US13/257,758 patent/US20120134985A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521198A5 (enExample) | ||
| US9119843B2 (en) | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions | |
| Bodine | The role of mTORC1 in the regulation of skeletal muscle mass | |
| Kumaresan et al. | Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming-and cue-induced reinstatement of cocaine seeking | |
| Price et al. | AMPK: An emerging target for modification of injury-induced pain plasticity | |
| Knight et al. | Chronic intermittent hypoxia increases blood pressure and expression of FosB/ΔFosB in central autonomic regions | |
| Bettany et al. | Ventral hippocampal α7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze | |
| LaCrosse et al. | Ceftriaxone attenuates cocaine relapse after abstinence through modulation of nucleus accumbens AMPA subunit expression | |
| Zhong et al. | Crosstalk between Cdk5/p35 and ERK1/2 signalling mediates spinal astrocyte activity via the PPARγ pathway in a rat model of chronic constriction injury | |
| Pantos et al. | Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor | |
| Chen et al. | Effects of histone deacetylase inhibitor sodium butyrate on heroin seeking behavior in the nucleus accumbens in rats | |
| Kelleher et al. | REDD2 expression in rat skeletal muscle correlates with nutrient-induced activation of mTORC1: responses to aging, immobilization, and remobilization | |
| Feleder et al. | Preoptic α1-and α2-noradrenergic agonists induce, respectively, PGE2-independent and PGE2-dependent hyperthermic responses in guinea pigs | |
| JP2021098745A (ja) | プラダー・ウィリー症候群を治療する方法 | |
| Lan et al. | Peroxisome Proliferator‐activated Receptor‐γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats | |
| Hongo et al. | Age-related effects of dexmedetomidine on myocardial contraction and coronary circulation in isolated guinea pig hearts | |
| JP2023109947A (ja) | 薬学的組成物 | |
| Puig et al. | Sex‐specific role of the circadian transcription factor NPAS2 in opioid tolerance, withdrawal and analgesia | |
| Peters et al. | Histamine: metabolism, physiology, and pathophysiology with applications in veterinary medicine | |
| Ohnuki et al. | Role of phosphodiesterase 4 expression in the Epac1 signaling‐dependent skeletal muscle hypertrophic action of clenbuterol | |
| WO2018035446A1 (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| US20160128954A1 (en) | Methods of Treating Huntington's Disease Using Cysteamine Compositions | |
| KR20100047860A (ko) | 신경병증 통증의 치료 | |
| Bright et al. | Targeting PPAR as a therapy to treat multiple sclerosis | |
| JP2012521364A5 (enExample) |